166 related articles for article (PubMed ID: 3666989)
1. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases.
Parish CR; Coombe DR; Jakobsen KB; Bennett FA; Underwood PA
Int J Cancer; 1987 Oct; 40(4):511-8. PubMed ID: 3666989
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the inhibition of tumour metastasis by sulphated polysaccharides.
Coombe DR; Parish CR; Ramshaw IA; Snowden JM
Int J Cancer; 1987 Jan; 39(1):82-8. PubMed ID: 2878892
[TBL] [Abstract][Full Text] [Related]
5. Evidence that platelet and tumour heparanases are similar enzymes.
Freeman C; Browne AM; Parish CR
Biochem J; 1999 Sep; 342 ( Pt 2)(Pt 2):361-8. PubMed ID: 10455023
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides.
Miao HQ; Elkin M; Aingorn E; Ishai-Michaeli R; Stein CA; Vlodavsky I
Int J Cancer; 1999 Oct; 83(3):424-31. PubMed ID: 10495437
[TBL] [Abstract][Full Text] [Related]
7. Thrombin enhances degradation of heparan sulfate in the extracellular matrix by tumor cell heparanase.
Benezra M; Vlodavsky I; Bar-Shavit R
Exp Cell Res; 1992 Jul; 201(1):208-15. PubMed ID: 1612123
[TBL] [Abstract][Full Text] [Related]
8. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells.
Savion N; Disatnik MH; Nevo Z
J Cell Physiol; 1987 Jan; 130(1):77-84. PubMed ID: 3805131
[TBL] [Abstract][Full Text] [Related]
9. Human platelet heparanase: purification, characterization and catalytic activity.
Freeman C; Parish CR
Biochem J; 1998 Mar; 330 ( Pt 3)(Pt 3):1341-50. PubMed ID: 9494105
[TBL] [Abstract][Full Text] [Related]
10. Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes.
Matzner Y; Bar-Ner M; Yahalom J; Ishai-Michaeli R; Fuks Z; Vlodavsky I
J Clin Invest; 1985 Oct; 76(4):1306-13. PubMed ID: 2997275
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of the ability of leucocytes, endothelial cells and platelets to degrade the subendothelial basement membrane: evidence for cytokine dependence and detection of a novel sulfatase.
Bartlett MR; Underwood PA; Parish CR
Immunol Cell Biol; 1995 Apr; 73(2):113-24. PubMed ID: 7797231
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of polysulfated polysaccharide on experimental encephalomyelitis, proliferation of autoimmune T cells, and inhibition of heparanase activity.
Hershkoviz R; Mor F; Miao HQ; Vlodavsky I; Lider O
J Autoimmun; 1995 Oct; 8(5):741-50. PubMed ID: 8579728
[TBL] [Abstract][Full Text] [Related]
13. Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells.
Bar-Ner M; Kramer MD; Schirrmacher V; Ishai-Michaeli R; Fuks Z; Vlodavsky I
Int J Cancer; 1985 Apr; 35(4):483-91. PubMed ID: 3157649
[TBL] [Abstract][Full Text] [Related]
14. Role of heparanase in platelet and tumor cell interactions with the subendothelial extracellular matrix.
Eldor A; Bar-Ner M; Yahalom J; Fuks Z; Vlodavsky I
Semin Thromb Hemost; 1987 Oct; 13(4):475-88. PubMed ID: 3321438
[TBL] [Abstract][Full Text] [Related]
15. Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix.
Bar-Ner M; Mayer M; Schirrmacher V; Vlodavsky I
J Cell Physiol; 1986 Aug; 128(2):299-306. PubMed ID: 2426287
[TBL] [Abstract][Full Text] [Related]
16. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties.
Lapierre F; Holme K; Lam L; Tressler RJ; Storm N; Wee J; Stack RJ; Castellot J; Tyrrell DJ
Glycobiology; 1996 Apr; 6(3):355-66. PubMed ID: 8724143
[TBL] [Abstract][Full Text] [Related]
17. Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix.
Bashkin P; Razin E; Eldor A; Vlodavsky I
Blood; 1990 Jun; 75(11):2204-12. PubMed ID: 1693299
[TBL] [Abstract][Full Text] [Related]
18. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation.
Vlodavsky I; Eldor A; Haimovitz-Friedman A; Matzner Y; Ishai-Michaeli R; Lider O; Naparstek Y; Cohen IR; Fuks Z
Invasion Metastasis; 1992; 12(2):112-27. PubMed ID: 1399400
[TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis.
Vlodavsky I; Korner G; Ishai-Michaeli R; Bashkin P; Bar-Shavit R; Fuks Z
Cancer Metastasis Rev; 1990 Nov; 9(3):203-26. PubMed ID: 1705486
[TBL] [Abstract][Full Text] [Related]
20. Differentiating human leukemia cells express heparanase that degrades heparan sulfate in subendothelial extracellular matrix.
Yahalom J; Fibach E; Bar-Tana R; Fuks Z; Vlodavsky I
Leuk Res; 1988; 12(9):711-7. PubMed ID: 2973542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
